Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines

American Journal of Veterinary Research

Volumn 69, Issue 7, 2008, Pages 938-945

  Kisseberth, William C ^a   Murahari, Sridhar ^a   London, Cheryl A ^a   Kulp, Samuel K ^a   Chen, Ching Shih ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; DIMETHYL SULFOXIDE; DNA; HISTONE; HISTONE DEACETYLASE INHIBITOR; N HYDROXY 4 (3 METHYL 2 PHENYL BUTYRYLAMINO)BENZAMIDE; PROPIDIUM IODIDE; VORINOSTAT;

ACETYLATION; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL POPULATION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DOG; DRUG POTENCY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTIOCYTIC LYMPHOMA; IC 50; INHIBITION KINETICS; MASTOCYTOMA; NONHUMAN; NUCLEOSOME; OSTEOSARCOMA; T CELL LYMPHOMA; WESTERN BLOTTING;

ACETYLATION; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DNA FRAGMENTATION; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLOW CYTOMETRY; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; INHIBITORY CONCENTRATION 50; NEOPLASMS; PHENYLBUTYRATES;

EID: 48049119672     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.69.7.938     Document Type: Article

References (27)

1. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-692.
2. Lin HY, Chen CS, Lin SP, et al. Targeting histone deacetylase in cancer therapy. Med Res Rev 2006;26:397-413.
3. Conley BA, Wright JJ, Kummar S. Targeting epigenetic abnormalities with histone deacetylase inhibitors. Cancer 2006;107:832-840.
4. Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202.
5. Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000;184:1-16.
6. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007;25:84-90.
7. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007;26:1351-1356.
8. 2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem 2004;47:467-474.
9. Lu Q, Wang DS, Chen CS, et al. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem 2005;48:5530-5535.
10. Kulp SK, Chen CS, Wang DS, et al. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC42, in prostate cancer. Clin Cancer Res 2006;12:5199-5206.
11. Lu YS, Kashida Y, Kulp SK, et al. Efficacy of OSU-HDAC42, a novel histone deacetylase inhibitor, in murine models of hepatocellular carcinoma. Hepatology 2007;46:1119-1130.
12. Cohen LA, Powers B, Amin S, et al. Treatment of canine haemangiosarcoma with suberoylanilide hydroamic acid, a histone deacetylase inhibitor. Vet Comp Oncol 2004;2:243-248.
13. Kisseberth WC, Nadella MV, Breen M, et al. A novel canine lymphoma cell line: a translational and comparative model for lymphoma research. Leuk Res. 2007;31:1709-1720.)
14. LeRoy BE, Thudi NK, Nadella MV, et al. New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenografl. Prostate 2006;66:1.213-1222.
15. Knapp DW, Chan TC, Kuczek T, et al. Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. Am J Vet Res 1995;56:801-805.
16. Forsberg LS, Lazarus SC, Seno N, et al. Dog mastocytoma proteoglycans: occurrence of heparin and oversulfated chondroitin sulfates, containing trisulfated disaccharides, in three cell lines. Biochim Biophys Acta 1988;967:416-428.
17. Shelly S, Chien MB, Yip B, et al. Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas. Mamm Gehome 2005;16:211-217.
18. Liao AT, McMahon M, London C. Characterization, expression, and function of c-Met in canine spontaneous cancers. Vet Comp Oncol 2005;3:61-72.
19. Papeleu P, Vanhaecke T, Elaut G, et al. Differential effects of histone deacetylase inhibitors in tumor and normal cells - what is the toxicological relevance? Crit Rev Toxicol 2005;35:363-378.
20. Garcia-Manero G, Issa JP. Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. Cancer Invest 2005;23:635-642.
21. Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;9:3578-3588.
22. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-3931.
23. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31-39.
24. Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001;98:2865-2868.
25. Zhang C, Richon V, Ni X, et al. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 2005;125:1045-1052.
26. Piekarz RL, Robey RW, Zhan Z, et al. T-cell lymphoma as a model for the use of histone deacetylase nihibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004; 103:4636-4643.
27. Yee SB, Kim MS, Baek SJ, et al. Trichostatin A induces apoptosis of p815 mastocytoma cells in histone acetylation- and mitochondria-dependent fashion. Int J Oncol 2004;25:1431-1436.